We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

121 hedge funds and large institutions have $383M invested in Progenics Pharmaceuticals Inc in 2015 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 39 increasing their positions, 44 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

44% more call options, than puts

Call options by funds: $1.02M | Put options by funds: $706K

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1% less capital invested

Capital invested by funds: $385M → $383M (-$2.68M)

9% less funds holding

Funds holding: 133121 (-12)

11% less repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 44

50% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 24

Holders
121
Holders Change
-12
Holders Change %
-9.02%
% of All Funds
3.17%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
12
Increased
39
Reduced
44
Closed
24
Calls
$1.02M
Puts
$706K
Net Calls
+$310K
Net Calls Change
+$56K
Name Holding Trade Value Shares
Change
Change in
Stake
Susquehanna International Group
76
Susquehanna International Group
Pennsylvania
$207K -$555K -84,606 -71%
VOYA Investment Management
77
VOYA Investment Management
Georgia
$195K
NIT
78
NumerixS Investment Technologies
British Columbia, Canada
$190K +$118K +17,936 +137%
AQR Capital Management
79
AQR Capital Management
Connecticut
$173K -$365K -55,733 -66%
IAM
80
Integre Asset Management
New York
$168K -$131K -19,964 -42%
VKH
81
Virtu KCG Holdings
New York
$155K -$57.4K -8,750 -26%
William Blair & Company
82
William Blair & Company
Illinois
$147K
RFC
83
Russell Frank Company
Washington
$126K -$1.21M -184,201 -90%
Bank of America
84
Bank of America
North Carolina
$122K -$44.8K -6,837 -26%
DSC
85
Duncker Streett & Co
Missouri
$115K -$32.8K -5,000 -21%
Jane Street
86
Jane Street
New York
$110K +$117K +17,920 New
Bank of Montreal
87
Bank of Montreal
Ontario, Canada
$106K +$31.9K +4,859 +39%
Morgan Stanley
88
Morgan Stanley
New York
$101K +$3.99K +609 +4%
BG
89
BlackRock Group
United Kingdom
$95K -$3.44K -525 -3%
BNP Paribas Financial Markets
90
BNP Paribas Financial Markets
France
$94.1K +$6.26K +955 +7%
Group One Trading
91
Group One Trading
Illinois
$89K +$71.5K +10,900 +305%
D.E. Shaw & Co
92
D.E. Shaw & Co
New York
$87K -$13.4K -2,041 -13%
Legal & General Group
93
Legal & General Group
United Kingdom
$79K
Canada Life
94
Canada Life
Manitoba, Canada
$75K
Principal Financial Group
95
Principal Financial Group
Iowa
$72K
American Century Companies
96
American Century Companies
Missouri
$69K
Royal Bank of Canada
97
Royal Bank of Canada
Ontario, Canada
$67K -$182K -27,719 -72%
SCM
98
Stevens Capital Management
Pennsylvania
$65K +$69.5K +10,602 New
Connor, Clark & Lunn Investment Management (CC&L)
99
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$62K +$66.2K +10,100 New
FM
100
Family Management
New York
$61K

PGNX Hedge Fund Activity: Q4 2015 in Review

121 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q4 2015, worth a combined $383M — down 0.7% from $385M a quarter earlier.

Sellers outnumbered buyers: 24 funds closed out of PGNX and 12 opened new positions — a net loss of 12 holders — while 44 trimmed existing stakes and 39 added.

The largest buyer was Rice Hall James & Associates, adding an estimated $2.69M. The largest seller was State Street, cutting an estimated $14.1M.

  • 121 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q4 2015, down from 133 in Q3 2015.
  • Funds reported $383M of Progenics Pharmaceuticals Inc stock for Q4 2015, down 0.7% quarter-over-quarter.
  • 12 funds opened new Progenics Pharmaceuticals Inc positions in Q4 2015 and 24 closed out, a net change of -12 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q4 2015 was Rice Hall James & Associates, an estimated $2.69M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q4 2015 was State Street, an estimated $14.1M sold.

Based on aggregated 13F filings for Q4 2015.